BRPI0801239A2 - uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase - Google Patents

uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase

Info

Publication number
BRPI0801239A2
BRPI0801239A2 BRPI0801239-3A BRPI0801239A BRPI0801239A2 BR PI0801239 A2 BRPI0801239 A2 BR PI0801239A2 BR PI0801239 A BRPI0801239 A BR PI0801239A BR PI0801239 A2 BRPI0801239 A2 BR PI0801239A2
Authority
BR
Brazil
Prior art keywords
disorders
treatment
prevention
pharmaceutical composition
benzopyranones
Prior art date
Application number
BRPI0801239-3A
Other languages
English (en)
Inventor
Queiroz Emerson Ferreira
Original Assignee
Ache Lab Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Lab Farmaceuticos Sa filed Critical Ache Lab Farmaceuticos Sa
Priority to BRPI0801239-3A priority Critical patent/BRPI0801239A2/pt
Priority to PCT/BR2009/000089 priority patent/WO2009121155A2/en
Publication of BRPI0801239A2 publication Critical patent/BRPI0801239A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM OU MAIS BENZOPIRANONAS, COMPOSIçãO FARMACêUTICA E MéTODO DE PREVENçãO OU TRATAMENTO DE DOENçAS, DISFUNçõES E DISTúRBIOS ASSOCIADOS A MONOAMINO OXIDASE. A presente invenção tem por objeto o uso de compostos benzopiranonas de fórmula (1) na fabricação de um medicamento útil no tratamento de doenças, disfunções e distúrbios associados a monoaminoxidase, composições farmacêuticas contendo tais compostos e método para prevenir ou tratar as mesmas.
BRPI0801239-3A 2008-04-01 2008-04-01 uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase BRPI0801239A2 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BRPI0801239-3A BRPI0801239A2 (pt) 2008-04-01 2008-04-01 uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
PCT/BR2009/000089 WO2009121155A2 (en) 2008-04-01 2009-04-01 Use of one or more benzopyranones, phamaceutical composmon and method for preventing or treating diseases, dysfunctions and disturbances associated to monoamine oxidase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0801239-3A BRPI0801239A2 (pt) 2008-04-01 2008-04-01 uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase

Publications (1)

Publication Number Publication Date
BRPI0801239A2 true BRPI0801239A2 (pt) 2009-11-17

Family

ID=41135963

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0801239-3A BRPI0801239A2 (pt) 2008-04-01 2008-04-01 uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase

Country Status (2)

Country Link
BR (1) BRPI0801239A2 (pt)
WO (1) WO2009121155A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102329312A (zh) * 2011-07-26 2012-01-25 苏州宝泽堂医药科技有限公司 一种夏佛塔苷的提纯方法
KR20150019505A (ko) * 2013-08-14 2015-02-25 대화제약 주식회사 플라본-6-c-글루코스 유도체를 유효성분으로 함유하는 신경정신질환의 치료 또는 예방용 약학적 조성물
ES2818097T3 (es) 2014-09-16 2021-04-09 Roar Holding Llc Bebidas energéticas y otras ayudas nutricionales derivadas de licores a base de agave
KR101818084B1 (ko) * 2015-04-14 2018-01-15 대구가톨릭대학교산학협력단 석송강 추출물 또는 이로부터 분리된 화합물을 포함하는 알츠하이머병의 예방 또는 치료용 조성물-ⅱ
ES2969066T3 (es) 2015-09-19 2024-05-16 Indus Biotech Private Ltd Composiciones que comprenden extractos de Fenogreco y métodos para producirlas
AU2019390401A1 (en) 2018-11-26 2021-06-24 Roar Holding Llc Methods to improve beverage quality
WO2021225343A1 (ko) * 2020-05-06 2021-11-11 한국한의학연구원 붓꽃 추출물을 포함하는 인지장애의 예방 또는 치료용 조성물
US12311005B2 (en) * 2020-09-11 2025-05-27 Tzung-Yan LEE Pharmaceutical compositions and uses thereof in treating Parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317071D0 (en) * 1993-08-17 1993-09-29 Univ Strathclyde Flavonoids
JPH0873360A (ja) * 1994-09-01 1996-03-19 Yoshihide Hagiwara 脳神経細胞障害抑制剤
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
BR0204228A (pt) * 2001-02-20 2004-06-22 Randy Ziegler Métodos para melhorar os sintomas de uma psicose e de esquizofrenia e para triar moléculas de teste, e, composto orgânico
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
BRPI0602106B8 (pt) * 2006-05-25 2021-05-25 Ache Laboratorios Farm S/A processo para preparação de um produto à base de passiflora incarnata l.
US7897637B2 (en) * 2006-07-19 2011-03-01 The Salk Institute For Biological Studies Methods of using flavonoids to enhance memory

Also Published As

Publication number Publication date
WO2009121155A3 (en) 2009-11-26
WO2009121155A2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
BRPI0609785B8 (pt) benzotiofenos substituídos por piperazina, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de benzotiofenos substituídos por piperazina ou um sal do mesmo, e, processo para produzir benzotiofenos substituídos por piperazina
BRPI0607017B8 (pt) composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
CO6150162A2 (es) Pirrolopirimidinas para composiciones farmaceuticas
NO20090321L (no) Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte
TW200505837A (en) Novel compounds
TW200519075A (en) Novel compounds
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
WO2006138660A3 (en) Sphingosine kinase inhibitors
PT1902037E (pt) 2,4-diamino-pirimidinas como inibidores de aurora
CL2008001839A1 (es) Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
JO2686B1 (en) Vehicles
TW200732296A (en) Novel compounds
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TW200745003A (en) Novel compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
TW200630336A (en) Novel compounds
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
BR112012021656A2 (pt) composto, uso do mesmo, e, composição farmacêutica
TW200621690A (en) Novel compounds

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL